PT-141
A cyclic heptapeptide melanocortin receptor agonist, also known as bremelanotide, with a completed regulatory development programme.
- Purity
- 99.2%
- Lot
- PU-0F2C
- CAS
- 189691-06-3
- MW
- 1025.16 g/mol
- Format
- Lyophilized powder
- Third-party tested
- Discreet packaging
- Same-day shipping
- Encrypted checkout
For research use only. Not for human consumption.
Mechanism of Action
PT-141 is a cyclic melanocortin receptor agonist derived from the alpha-MSH scaffold. It acts centrally on melanocortin receptors rather than on vascular tissue, which distinguishes its pharmacology from that of peripherally acting agents.
The melanocortin receptor family comprises five subtypes with distinct distributions, and the pharmacology literature - including a 2023 Nature Reviews Endocrinology review of the central melanocortin system and a 2023 review of MC1R specifically - is largely concerned with subtype selectivity.
Research Findings
A 2004 profile in Current Opinion in Investigational Drugs documents the early programme, and a 2019 Drugs entry records the regulatory approval of bremelanotide. A 2022 paper in the Journal of Women's Health reported the safety profile assembled across the clinical development programme.
Related melanocortin pharmacology includes a 2017 Molecular Metabolism evaluation of an MC4R agonist in MC4R deficiency. The receptor-level literature is substantially larger than the literature on this specific molecule.
Storage & Reconstitution
Sealed lyophilized vials are stored in the dark. The peptide-formulation literature regards the dry solid as the stable state and the solution as the fragile one: refrigeration at 2-8 degrees C is standard for short holding periods, and minus 20 degrees C or colder for long-term storage. Vials are brought to room temperature before opening so that atmospheric moisture does not condense onto the cold solid.
For reconstitution, the diluent is added slowly down the inner wall of the vial rather than directly onto the cake, and the vial is swirled rather than shaken - agitation at an air-liquid interface is a well-documented driver of peptide aggregation. The solid should dissolve to a clear, particle-free solution; persistent cloudiness or visible particulate indicates the material should not be used.
Reconstituted solution is held at 2-8 degrees C and protected from light. Freeze-thaw cycling is the single most avoidable cause of loss, so where a solution must be frozen it is aliquoted first into single-use volumes. Working aliquots are labelled with the lot number so that any result can be traced back to the certificate of analysis for that lot.
- Physical form
- Lyophilized powder, sealed vial
- Sealed storage
- 2-8 C short term / -20 C long term
- Reconstituted
- 2-8 C, protected from light
- Diluent
- Bacteriostatic water, added down the vial wall
- Avoid
- Shaking, freeze-thaw cycling, direct light
Handling summary
References
Every entry below links to its PubMed record. Publication is not endorsement: several of these papers report limitations, negative findings or adverse events, and they are listed for that reason.
- [1]PT-141 Palatin(opens PubMed in a new tab)
Curr Opin Investig Drugs · 2004 · PMID 15134289
- [2]Bremelanotide: First Approval(opens PubMed in a new tab)
Drugs · 2019 · PMID 31429064
- [3]Targeting the central melanocortin system for the treatment of metabolic disorders(opens PubMed in a new tab)
Nat Rev Endocrinol · 2023 · PMID 37365323
- [4]Safety Profile of Bremelanotide Across the Clinical Development Program(opens PubMed in a new tab)
J Womens Health (Larchmt) · 2022 · PMID 35147466
- [5]Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency(opens PubMed in a new tab)
Mol Metab · 2017 · PMID 29031731
- [6]Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects(opens PubMed in a new tab)
Int J Mol Sci · 2023 · PMID 37569558